[A21-127] Vandetanib (medullary thyroid cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the limitation period)
Last updated 03.01.2022
Project no.:
A21-127
Commission:
Commission awarded on 01.10.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Treatment of aggressive and symptomatic medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease
Added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-01 | Vandetanib (medullary thyroid carcinoma in children and adolescents from the age of 5) – Benefit assessment according to § 35a Social Code Book V | Commission completed |
| A13-09 | Vandetanib (second assessment) - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
| A12-09 | Vandetanib - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |